TWD 20.55
(-8.46%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 883.97 Million TWD | -8.87% |
2022 | 970.03 Million TWD | -9.86% |
2021 | 1.07 Billion TWD | 14.47% |
2020 | 940.12 Million TWD | -5.08% |
2019 | 990.42 Million TWD | -11.89% |
2018 | 1.12 Billion TWD | 15.16% |
2017 | 976.1 Million TWD | -5.51% |
2016 | 1.03 Billion TWD | 24.45% |
2015 | 830.05 Million TWD | 50.34% |
2014 | 552.1 Million TWD | -7.91% |
2013 | 599.52 Million TWD | 3.65% |
2012 | 578.38 Million TWD | 24.75% |
2011 | 463.63 Million TWD | 48.44% |
2010 | 312.33 Million TWD | -15.36% |
2009 | 369.02 Million TWD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | 921.19 Million TWD | 4.21% |
2024 Q2 | 806.98 Million TWD | -12.4% |
2023 Q3 | 885.08 Million TWD | -4.9% |
2023 Q1 | 911.75 Million TWD | -6.01% |
2023 FY | 883.97 Million TWD | -8.87% |
2023 Q4 | 883.97 Million TWD | -0.12% |
2023 Q2 | 930.69 Million TWD | 2.08% |
2022 Q3 | 1.03 Billion TWD | -8.74% |
2022 FY | 970.03 Million TWD | -9.86% |
2022 Q4 | 970.03 Million TWD | -6.27% |
2022 Q1 | 1.08 Billion TWD | 0.4% |
2022 Q2 | 1.13 Billion TWD | 4.97% |
2021 FY | 1.07 Billion TWD | 14.47% |
2021 Q3 | 1.03 Billion TWD | 1.89% |
2021 Q4 | 1.07 Billion TWD | 3.65% |
2021 Q1 | 958.93 Million TWD | 2.0% |
2021 Q2 | 1.01 Billion TWD | 6.26% |
2020 Q2 | 1.11 Billion TWD | 28.73% |
2020 FY | 940.12 Million TWD | -5.08% |
2020 Q3 | 1.15 Billion TWD | 2.84% |
2020 Q4 | 940.12 Million TWD | -18.27% |
2020 Q1 | 868.76 Million TWD | -12.28% |
2019 Q1 | 1.23 Billion TWD | 10.27% |
2019 Q3 | 1.2 Billion TWD | -7.71% |
2019 Q4 | 990.42 Million TWD | -17.83% |
2019 FY | 990.42 Million TWD | -11.89% |
2019 Q2 | 1.3 Billion TWD | 5.37% |
2018 Q2 | 1.05 Billion TWD | 15.17% |
2018 Q3 | 1.01 Billion TWD | -3.9% |
2018 Q4 | 1.12 Billion TWD | 10.63% |
2018 Q1 | 918.08 Million TWD | -5.94% |
2018 FY | 1.12 Billion TWD | 15.16% |
2017 Q1 | 973.66 Million TWD | -5.74% |
2017 FY | 976.1 Million TWD | -5.51% |
2017 Q4 | 976.1 Million TWD | -3.96% |
2017 Q3 | 1.01 Billion TWD | -7.66% |
2017 Q2 | 1.1 Billion TWD | 13.05% |
2016 Q2 | 972.48 Million TWD | 3.28% |
2016 Q3 | 874.55 Million TWD | -10.07% |
2016 Q4 | 1.03 Billion TWD | 18.12% |
2016 Q1 | 941.61 Million TWD | 13.44% |
2016 FY | 1.03 Billion TWD | 24.45% |
2015 FY | 830.05 Million TWD | 50.34% |
2015 Q4 | 830.05 Million TWD | -14.66% |
2015 Q3 | 972.67 Million TWD | 45.57% |
2015 Q1 | 534.68 Million TWD | -3.16% |
2015 Q2 | 668.16 Million TWD | 24.97% |
2014 Q2 | 758.65 Million TWD | 2.58% |
2014 FY | 552.1 Million TWD | -7.91% |
2014 Q1 | 739.55 Million TWD | 23.36% |
2014 Q3 | 637.83 Million TWD | -15.93% |
2014 Q4 | 552.1 Million TWD | -13.44% |
2013 Q1 | 581.1 Million TWD | 0.47% |
2013 FY | 599.52 Million TWD | 3.65% |
2013 Q4 | 599.52 Million TWD | -2.03% |
2013 Q3 | 611.94 Million TWD | -2.1% |
2013 Q2 | 625.04 Million TWD | 7.56% |
2012 Q1 | 425.96 Million TWD | -8.13% |
2012 FY | 578.38 Million TWD | 24.75% |
2012 Q4 | 578.38 Million TWD | -13.53% |
2012 Q3 | 668.86 Million TWD | 18.25% |
2012 Q2 | 565.61 Million TWD | 32.79% |
2011 Q2 | 447.23 Million TWD | 29.76% |
2011 FY | 463.63 Million TWD | 48.44% |
2011 Q1 | 344.65 Million TWD | 10.35% |
2011 Q3 | 300.36 Million TWD | -32.84% |
2011 Q4 | 463.63 Million TWD | 54.36% |
2010 FY | 312.33 Million TWD | -15.36% |
2010 Q4 | 312.33 Million TWD | 0.0% |
2009 FY | 369.02 Million TWD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Excelsior Medical Co., Ltd. | 7.16 Billion TWD | 87.666% |
OK Biotech Co., Ltd. | 672.26 Million TWD | -31.492% |
Applied BioCode Corporation | 332.21 Million TWD | -166.084% |